Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Slides
Videos-PodcastsVideos & Podcasts

Quicksearch

DOP05: Morbid obesity, a new susceptibility factor for developing Inflammatory Bowel Disease. Results of a population-based studyECCO'22
Year: 2022
Authors: Canete Pizarro, F.C.(1);Vela, E.(2);Calafat, M.(1);Clèries, M.(2);Mañosa, M.(1);Domènech, E.(1);
(1)Germans Trias i Pujol University Hospital and CIBEREHD, Gastroenterology, Badalona, Spain;(2)Servei Català de la Salut- Generalitat de Catalunya, Unitat d’Informació i Coneixement, Barcelona, Spain;
DOP06: Antibiotics as a risk factor for older onset IBD: A population-based cohort studyECCO'22
Year: 2022
Authors: Faye, A.(1);Allin, K.(2);Iversen, A.(2);Agrawal, M.(3);Faith, J.(4);Jean-Frederic , C.(3);Jess, T.(2);
(1)NYU Langone Health, Medicine, New York City, United States;(2)Aalborg University, Medicine, Copenhagen, Denmark;(3)Icahn School of Medicine- Mount Sinai Hospital, Medicine, New York City, United States;(4)Icahn School of Medicine- Mount Sinai Hospital, Genetics and Genomics Science, New York City, United States;
DOP07: Chronic abdominal pain in IBD patients in remission: Real-world data on contributing factorsECCO'22
Year: 2022
Authors: Rezazadeh Ardabili, A.(1,2);Janssen, L.M.(1,2);Romberg-Camps, M.J.L.(3);Keszthelyi, D.(1,2);Jonkers, D.M.A.E.(1,2);van Bodegraven, A.A.(3);Pierik, M.J.(1,2);Mujagic, Z.(1,2);
(1)Department of Internal Medicine- Division of Gastroenterology and Hepatology, Maastricht University Medical Center+, Maastricht, The Netherlands;(2)School for Nutrition and Translational Research in Metabolism NUTRIM, Maastricht University Medical Center+, Maastricht, The Netherlands;(3)Department of Gastroenterology- Geriatrics- Internal and Intensive Care Medicine Co-MIK, Zuyderland Medical Centre, Heerlen-Sittard-Geleen, The Netherlands;
DOP08: Transcriptional signatures of blood derived immune cells associated with disease location-based heterogeneity in IBDECCO'22
Year: 2022
Authors: Sudhakar, P.(1);Verstockt, B.(1,2);Cremer, J.(3);Verstockt, S.(1);Sabino, J.(1,2);Ferrante, M.(1,2);Vermeire, S.(1,2);
(1)KU Leuven, Department of Chronic Diseases- Metabolism and Ageing - TARGID, Leuven, Belgium;(2)University Hospitals Leuven, Department of Gastroenterology and Hepatology- KU Leuven, Leuven, Belgium;(3)KU Leuven, Department of Microbiology and Immunology- Laboratory of Clinical Immunology, Leuven, Belgium;
DOP09: Phenotypic and genetic determinants of medication response in patients in the UK IBD BioResourceECCO'22
Year: 2022
Authors: Zhang, Q.(1);Fachal, L.(1);Shawky, R.(2);Lamb, C.(3,4);Parkes, M.(2,5,6);Anderson, C.(1);Raine, T.(1,6);
(1)Wellcome Trust Sanger Institute, Human Genetics, Cambridge, United Kingdom;(2)Cambridge University Hospitals NHS Foundation Trust, IBD BioResource- NIHR BioResource, Cambridge, United Kingdom;(3)Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle, United Kingdom;(4)Newcastle upon Tyne Hospitals NHS Foundation Trust, Department of Gastroenterology, Newcastle, United Kingdom;(5)University of Cambridge, Division of Gastroenterology and Hepatology- Department of Medicine, Cambridge, United Kingdom;(6)Cambridge University Hospitals NHS Foundation Trust, Department of Gastroenterology, Cambridge, United Kingdom;
DOP10: Intestinal Ultrasound at IBD diagnosis predicts major disease events – A Copenhagen IBD cohort studyECCO'22
Year: 2022
Authors: Madsen, G.R.(1);Attauabi, M.(2);Wilkens, R.(1);Ilvemark, J.F.K.F.(2);Theede, K.(1);Bjerrum, J.T.(2);Dorn-Rasmussen, M.(3);Jansson, S.(3);Wewer, A.V.(3);Bendtsen, F.(1);Seidelin, J.B.(2);Boysen, T.(1);Burisch, J.(1);
(1)Hvidovre Hospital - University of Copenhagen, Gastrounit - Medical division, Hvidovre, Denmark;(2)Herlev University Hospital, Department of Gastroenterology and Hepatology, Herlev, Denmark;(3)Hvidovre Hospital - University of Copenhagen, The Paediatric Department, Hvidovre, Denmark;
DOP11: Early intestinal ultrasound predicts endoscopic response to anti-inflammatory treatment and shows drug-specific response to biologicals and tofacitinib in Ulcerative ColitisECCO'22
Year: 2022
Authors: de Voogd, F.(1);Bots, S.(1);Van Wassenaer, E.(2);De Jong, M.(1);Pruijt, M.(1);Löwenberg, M.(1);D'Haens, G.(1);Gecse, K.(1);
(1)Amsterdam University Medical Center, Gastroenterology and Hepatology, Amsterdam, The Netherlands;(2)Emma Children's Hospital- Amsterdam University Medical Center, Pediatric Gastroenterology, Amsterdam, The Netherlands;
DOP12: Non-invasive assessment of intestinal inflammatory activity in Ulcerative Colitis by Multispectral Optoacoustic Tomography (MSOT)ECCO'22
Year: 2022
Authors: Klett, D.(1);Jesper, D.(1);Vitali, F.(1);Federle, A.(1);Atreya, R.(1);Strobel, D.(1);Leppkes, M.(1);Neufert, C.(1);Rath, T.(1);Neurath, M.F.(1);Waldner, M.J.(1);
(1)University Hospital Erlangen-Nuremberg, Department of Medicine I, Erlangen, Germany;
DOP13: The Arborisation index: An MRI-based measure of mesenteric hyperaemia in Crohn’s DiseaseECCO'22
Year: 2022
Authors: Naim, I.(1,2);Darie, A.M.(1,2);Hoad, C.(2,3);Gowland, P.(2,3);Moran, G.W.(1,2);
(1)University of Nottingham, School of Medicine, Nottingham, United Kingdom;(2)Nottingham University Hospitals NHS Trust and University of Nottingham, National Institute of Health Research- Nottingham Biomedical Research Centre, Nottingham, United Kingdom;(3)University of Nottingham, School of Physics and Astronomy, Nottingham, United Kingdom;
DOP14: Validation of a new OPtical diagnosis Training platform to Improve dysplasia Characterisation in Inflammatory Bowel Disease (OPTIC-IBD): A multicentre randomised controlled studyECCO'22
Year: 2022
Authors: Iacucci , M.(1,2);Ingram , R.J.M.(1,2);Bazarova , A.(3);Cannatelli , R.(4);Labarile , N.(5);Nardone , O.M.(6);Parigi , T.L.(1,7);Siau , K.(8);Smith , S.C.L.(1);Ferraz , J.G.P.(2);Kiesslich , R.(9);Panaccione , R.(2);Parra-Blanco , A.(10);Tontini , G.E.(11,12);Uraoka , T.(13);Ghosh , S.(14);
(1)University of Birmingham, Institute of Immunology and Immunotherapy, Birmingham, United Kingdom;(2)University of Calgary, Cumming School of Medicine, Calgary, Canada;(3)University of Cologne, Institute for Biological Physics, Köln, Germany;(4)University of Milan ASST Fatebenefratelli Sacco, Department of Biochemical and Clinical Sciences 'L Sacco', Milano, Italy;(5)National Institute of Research 'Saverio De Bellis', Section of Gastroenterology, Castellana Grotte, Italy;(6)School of Medicine Federico II of Naples, Gastroenterology Unit- Department of Clinical Medicine and Surgery, Napoli, Italy;(7)Humanitas University, Department of Biomedical Sciences, Milano, Italy;(8)Royal Cornwall Hospitals NHS Trust, Department of Gastroenterology, Truro, United Kingdom;(9)Helios Horst-Schmidt-Kliniken Hospital, Division of Gastroenterology, Wiesbaden, Germany;(10)Nottingham University Hospitals NHS Trust, Department of Gastroenterology, Nottingham, United Kingdom;(11)University of Milan, Department of Pathophysiology and Organ Transplantation, Milano, Italy;(12)Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Gastroenterology and Digestive Endoscopy Unit, Milano, Italy;(13)Gunma University Graduate School of Medicine, Department of Gastroenterology and Hepatology, Maebashi, Japan;(14)University College Cork, APC Microbiome Ireland, Cork, Ireland;OPTIC-IBD Study Group
DOP15: Fluorescent labelled vedolizumab for real-time visualization and quantification of local drug distribution and pharmacodynamics in Inflammatory Bowel Diseases during endoscopyECCO'22
Year: 2022
Authors: Gabriëls, R.Y.(1);Linssen, M.(1);van der Waaij, A.(1);Volkmer, P.(1);Hooghiemstra, W.(1);Kats-Ugurlu, G.(2);Robinson, D.(3);Dijkstra, G.(1);Nagengast, W.(1);
(1)University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, The Netherlands;(2)University Medical Center Groningen, Department of Pathology and Medical Biology, Groningen, The Netherlands;(3)University Medical Center Erasmus Rotterdam, Optic Diagnostics and Therapy, Rotterdam, The Netherlands;
DOP16: Categorizing endoscopic severity of Crohn’s Disease using the Modified Multiplier SES-CD (MM-SES-CD)ECCO'22
Year: 2022
Authors: Narula, N.(1);Pray, C.(1);Wong, E.(1);Colombel, J.F.(2);Marshall, J.(1);Daperno, M.(3);Reinisch, W.(4);Dulai, P.(5);
(1)McMaster University, Department of Medicine Division of Gastroenterology, Hamilton, Canada;(2)Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, United States;(3)AO Ordine Mauriziano di Torino, Gastroenterology Unit, Turin, Italy;(4)Medical University of Vienna, Department of Internal Medicine III Division of Gastroenterology and Hepatology, Vienna, Austria;(5)University of California San Diego, Division of Gastroenterology, La Jolla, United States;
DOP17: Evaluating segmental healing with the modified Mayo endoscopic score (MMES) has a clear additional value in predicting long-term outcome in patients with Ulcerative Colitis: Results from a prospective cohort studyECCO'22
Year: 2022
Authors: Lenfant, M.(1,2);Verstockt, B.(1,2);Sabino, J.(1,2);Vermeire, S.(1,2);Ferrante, M.(1,2);
(1)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(2)KU Leuven, Translational Research in Gastrointestinal Disorders, Leuven, Belgium;
DOP18: Advanced optical diagnosis technology for assessment of endoscopic and histological remission in Ulcerative Colitis: A systematic review and meta-analysisECCO'22
Year: 2022
Authors: Nardone, O.M.(1);Snir , Y.(2,3);Hodson, J.(4);Cannatelli, R.(1);Labarile, N.(1);Siau, K.(1,5);Hassan, C.(6);Yanai, H.(2,3);Dotan, I.(2,3);Ghosh, S.(1,7,8,9);Iacucci, M.(1,8,9);
(1)University of Birmingham, Institute of Translational Medicine and Institute of Immunology and Immunotherapy, Birmingham, United Kingdom;(2)Rabin Medical Center- Beilinson Campus- Petach-Tikva Israel, Division of Gastroenterology, Petach-Tikva, Israel;(3)Tel Aviv University- Tel Aviv- Israel, Sackler Faculty of Medicine, Tel Aviv, Israel;(4)University Hospitals Birmingham NHS Foundation Trust- Birmingham- UK., Department of Health Informatics-, Birmingham, United Kingdom;(5)Royal Cornwall Hospitals NHS Trust- Truro- UK, Department of Gastroenterology-, Truro, United Kingdom;(6)Nuovo Regina Margherita Hospital- Roma- Italy, Department of Gastroenterology, Rome, Italy;(7)University College Cork- Cork- Ireland, APC Microbiome Ireland- College of Medicine and Health, Cork, Ireland;(8)University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, NIHR Biomedical Research Centre, Birmingham, United Kingdom;(9)University Hospitals Birmingham NHS Trust- Birmingham- UK, NIHR Wellcome Trust Clinical Research Facilities, Birmingham, United Kingdom;
DOP19: Myeloid and lymphoid cell abnormalities persist in the intestinal mucosa of patients who recover from COVID-19 infectionECCO'22
Year: 2022
Authors: Meringer, H.(1);Tokuyama, M.(1);Tankelevich, M.(1);Martinez-Delgado, G.(1);Jha, D.(1); Livanos, A.E.(1);Canales-Herrerias, P.(1);Cossarini, F.(2);Mehandru , S.(1);
(1)Icahn School of medicine at Mount Sinai, Division of Gastroenterology- Department of Medicine, New York, United States;(2)Icahn School of medicine at Mount Sinai, Division of Infectious Disease- Department of Medicine, New York, United States;
DOP20: Functional viral neutralisation responses after SARS-CoV-2 infection in Inflammatory Bowel Disease patients receiving infusion therapies: Report from the ICARUS-IBD ConsortiumECCO'22
Year: 2022
Authors: Wellens, J.(1,2);Edmans, M.(3);Obolski, U.(4,5);Marlow, L.(1);Brann, S.(1);Dunachie, S.(3,6,7);Eyre, D.(8,9);Helmus, D.(10);Barnes, E.(1,3);Colombel, J.F.(10);Wong, S.Y.(10);Klenerman, P.(1,3);Lindsay, J.O.(11,12);Thompson, C.P.(13);Satsangi, J.(1);
(1)University of Oxford, Translational Gastro-­Intestinal Unit- Nuffield Department of Medicine, Oxford, United Kingdom;(2)University hospitals Leuven, Translational Research for Gastrointestinal Diseases, Leuven, Belgium;(3)University of Oxford, Peter Medawar Building for Pathogen Research, Oxford, United Kingdom;(4)Tel-Aviv University, Porter School of Environmental and Earth Sciences- Faculty of Exact Sciences, Tel-Aviv, Israel;(5)Tel-Aviv University, School of Public Health- Faculty of Medicine, Tel-Aviv, Israel;(6)Oxford University Hospitals- NHS, Department of Microbiology/Infectious Diseases, Oxford, United Kingdom;(7)University of Oxford, Centre for Tropical Medicine and Global Health- Nuffield Department of Medicine, Oxford, United Kingdom;(8)University of Oxford, Big Data Institute, Oxford, United Kingdom;(9)University of Oxford, Infectious Diseases & Medical Microbiology, Oxford, United Kingdom;(10)Icahn School of Medicine at Mount Sinai- New York, The Henry D. Janowitz Division of Gastroenterology- Department of Medicine, New York, United States;(11)The Royal London Hospital, Barts Health NHS Trust- department of Gastroenterology, London, United Kingdom;(12)Blizard Institute- Barts and the London School of Medicine  Queen Mary University of London, Centre for Immunobiology, London, United Kingdom;(13)University of Oxford, Department of Zoology, Oxford, United Kingdom;The ICARUS-IBD CONSORTIUM
DOP21: Potential mechanisms linking biological therapies on SARS-CoV-2 susceptibility in Inflammatory Bowel Disease patientsECCO'22
Year: 2022
Authors: Pisani, L.F.(1);Mola, S.(2,3);Crespi, G.(2,3);Caprioli, F.(4,5);Pastorelli, L.(6,7);Annunziata, M.L.(1);Manfredi, M.(3,8);Porta, C.(2,3);
(1)IRCCS Policlinico San Donato, Gastroenterology and Endoscopy Unit, San Donato Milanese, Italy;(2)University of Piemonte Orientale, Department of Pharmaceutical Sciences, Novara, Italy;(3)University of Piemonte Orientale, Center for Translational Research on Autoimmune and Allergic Diseases, Novara, Italy;(4)University of Milan, Department of Medical-Surgical Physiopathology and Transplantation, Milan, Italy;(5)Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Gastroenterology and Endoscopy Unit, Milan, Italy;(6)University of Milan, Department of Health Sciences, Milan, Italy;(7)ASST Santi Paolo e Carlo, Gastroenterology and Liver Unit, Milan, Italy;(8)University of Piemonte Orientale, Department of Translational Medicine, Novara, Italy;
DOP22: Clinical, biochemical and endoscopic disease activity of Inflammatory Bowel Diseases are not associated with the severity or long-term outcomes of COVID-19 – A Danish prospective population-based cohort studyECCO'22
Year: 2022
Authors: Attauabi, M.(1,2,3);Dahlerup, J.F.(4);Poulsen, A.(5);Hansen, M.R.(6);Vester-Andersen, M.K.(7);Eraslan, S.(2);Prahm, A.P.(5);Pedersen, N.(8);Larsen, L.(9);Jess, T.(9,10);Neumann, A.(11);Haderslev, K.V.(12);Molazahi, A.(13);Lødrup, A.B.(14);Glerup, H.(15);Oppfeldt, A.M.(16);Jensen, M.D.(17);Theede, K.(1,3);Kiszka-Kanowitz, M.(1,3);Seidelin, J.B.(2);Burisch, J.(1,3); Danish COVID-IBD Study Group
(1)Copenhagen University Hospital- Hvidovre, Gastrounit- Medical Section, Hvidovre, Denmark;(2)Herlev Hospital- University of Copenhagen, Department of Gastroenterology and Hepatology, Herlev, Denmark;(3)University of Copenhagen- Hvidovre Hospital, Copenhagen Center for Inflammatory Bowel Disease in Children- Adolescents and Adults, Hvidovre, Denmark;(4)Aarhus University Hospital, Department of Hepatology and Gastroenterology, Aarhus, Denmark;(5)Bispebjerg University Hospital, Digestive Disease Center, Copenhagen, Denmark;(6)North Zealand University Hospital, Department of Gastroenterology, Frederikssund, Denmark;(7)Zealand University Hospital- Koege, Department of Internal Medicine, Koege, Denmark;(8)Slagelse Hospital, Department of Gastroenterology, Slagelse, Denmark;(9)Aalborg University Hospital, Department of Gastroenterology and Hepatology, Aalborg, Denmark;(10)Aalborg University, National Center of Excellence for Molecular Prediction of Inflammatory Bowel Disease PREDICT- Department of Clinical Medicine, Copenhagen, Denmark;(11)Region Hospital Viborg, Department of Internal Medicine, Viborg, Denmark;(12)Rigshospitalet- Copenhagen University Hospital, Department of Gastroenterology, Copenhagen, Denmark;(13)Holbaek Hospital, Department of Internal Medicine, Holbaek, Denmark;(14)Region Hospital West Jutland- Herning, Department of Internal Medicine, Herning, Denmark;(15)Region Hospital Silkeborg, Department of Internal Medicine, Silkeborg, Denmark;(16)Region Hospital Horsens, Department of Internal Medicine, Horsens, Denmark;(17)Lillebaelt Hospital- Vejle, Department of Internal Medicine- Section of Gastroenterology, Vejl, Denmark;
DOP23: Long-term health consequences of COVID-19 in patients with Inflammatory Bowel Diseases – A Danish prospective population-based cohort studyECCO'22
Year: 2022
Authors: Attauabi, M.(1,2,3);Dahlerup, J.F.(4);Poulsen, A.(5);Hansen, M.R.(6);Vester-Andersen, M.K.(7);Eraslan, S.(2);Prahm, A.P.(5);Pedersen, N.(8);Larsen, L.(9);Jess, T.(9,10);Neumann, A.(11);Haderslev, K.V.(12);Molazahi, A.(13);Lødrup, A.B.(14);Glerup, H.(15);Oppfeldt, A.M.(16);Jensen, M.D.(17);Theede, K.(1,3);Kiszka-Kanowitz, M.(1,3);Seidelin, J.B.(2);Burisch, J.(1,3); Danish COVID-IBD Study Group
(1)Copenhagen University Hospital- Hvidovre, Gastrounit- Medical Section, Hvidovre, Denmark;(2)Herlev Hospital- University of Copenhagen, Department of Gastroenterology and Hepatology, Herlev, Denmark;(3)University of Copenhagen- Hvidovre Hospital, Copenhagen Center for Inflammatory Bowel Disease in Children- Adolescents and Adults, Hvidovre, Denmark;(4)Aarhus University Hospital, Department of Hepatology and Gastroenterology, Aarhus, Denmark;(5)Bispebjerg University Hospital, Digestive Disease Center, Copenhagen, Denmark;(6)North Zealand University Hospital, Department of Gastroenterology, Frederikssund, Denmark;(7)Zealand University Hospital- Koege, Department of Internal Medicine, Koege, Denmark;(8)Slagelse Hospital, Department of Gastroenterology, Slagelse, Denmark;(9)Aalborg University Hospital, Department of Gastroenterology and Hepatology, Aalborg, Denmark;(10)Aalborg University, National Center of Excellence for Molecular Prediction of Inflammatory Bowel Disease PREDICT- Department of Clinical Medicine, Copenhagen, Denmark;(11)Region Hospital Viborg, Department of Internal Medicine, Viborg, Denmark;(12)Rigshospitalet- Copenhagen University Hospital, Department of Gastroenterology, Copenhagen, Denmark;(13)Holbaek Hospital, Department of Internal Medicine, Holbaek, Denmark;(14)Region Hospital West Jutland- Herning, Department of Internal Medicine, Herning, Denmark;(15)Region Hospital Silkeborg, Department of Internal Medicine, Silkeborg, Denmark;(16)Region Hospital Horsens, Department of Internal Medicine, Horsens, Denmark;(17)Lillebaelt Hospital, Department of Internal Medicine- Section of Gastroenterology, Vejle, Denmark;
DOP24: Japan prospective multicenter study for optimization of COVID-19 vaccinations based on the immune response and safety profile in Inflammatory Bowel Disease patients: Interim analyses of the J-COMBAT trialECCO'22
Year: 2022
Authors: WatanabeDirector of division- Assistan, K.(1);Hisamatsu, T.(2);Nakase, H.(3);Nagase, K.(1);Matsuura, M.(2);Aoyama, N.(4);Kobayashi, T.(5);Sakuraba, H.(6);Yokoyama, K.(7);Nishishita, M.(8);Esaki , M.(9);Hirai, F.(10);Nagahori, M.(11);Nanjo, S.(12);Omori, T.(13);Tanida, S.(14);Yokoyama, Y.(3);Moriya, K.(15);Maemoto, A.(16);Handa, O.(17);Ohmiya, N.(18);Shinzaki, S.(19);Kato, S.(20);Tanaka, H.(21);Uraoka, T.(22);Takatsu, N.(23);Suzuki, H.(24);Takahashi, K.(25);Umeno, J.(26);Mishima, Y.(27);Tsuchida, K.(28);Fujiya, M.(29);Hiraoka, S.(30);Yamamoto, S.(31);Saruta, M.(32);Nojima, M.(33);Andoh, A.(25);
(1)Hyogo College of Medicine, Center for Inflammatory Bowel Disease- Division of Internal Medicine, Hyogo, Japan;(2)Kyorin University School of Medicine, Department of Gastroenterology and Hepatology, Tokyo, Japan;(3)Sapporo Medical University School of Medicine, Gastroenterology and Hepatology, Sapporo, Japan;(4)Aoyama Medical Clinic, Gastroenterology, Kobe, Japan;(5)Kitasato University Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan;(6)Hirosaki University Graduate School of Medicine, Gastroenterology and Hematology, Hirosaki, Japan;(7)Kitasato University School of Medicine, Department of Gastroenterology, Sagamihara, Japan;(8)Nishishita GI Hospital, Gastroenterology, Osaka, Japan;(9)Saga University, Division of Gastroenterology- Department of Internal Medicine, Saga, Japan;(10)Faculty of Medicine Fukuoka University, Gastroenterology, Fukuoka, Japan;(11)Tokyo Medical and Dental University Hospital, Gastroenterology and Hepatology, Tokyo, Japan;(12)University of Toyama, Third Department of Internal Medicine- Graduate School of Medicine, Toyama, Japan;(13)Tokyo Women’s Medical University, Institute of Gastroenterology, Tokyo, Japan;(14)Nagoya City University, Gastroenterology and Metabolism, Nagoya, Japan;(15)Nara Medical University, Department of Gastroenterology and Hepatology, Kashihara, Japan;(16)Sapporo Higashi Tokushukai Hospital, Inflammatory Bowel Disease Center, Sapporo, Japan;(17)Kawasaki Medical School, Internal Medicine- Division of Gastroenterology, Kurashiki, Japan;(18)Fujita Health University, Department of Advanced Endoscopy, Toyoake, Japan;(19)Osaka University Graduate School of Medicine, Gastroenterology and Hepatology, Suita, Japan;(20)Saitama Medical Center- Saitama Medical University, Department of Gastroenterology and Hepatology, Kawagoe, Japan;(21)Sapporo IBD Clinic, Inflammatory Bowel Disease, Sapporo, Japan;(22)Gunma University Graduate School of Medicine, Department of Gastroenterology and Hepatology, Maebashi, Japan;(23)Fukuoka University Chikushi Hospital, Inflammatory bowel disease center, Chikushino, Japan;(24)Faculty of Medicine- University of Tsukuba, Gastroenterology, Tsukuba, Japan;(25)Shiga University of Medical Science, Gastroenterology, Otsu, Japan;(26)Kyushu University, Medicine and Clinical Science- Graduate School of Medical Sciences Graduate School of Medical Sciences, Fukuoka, Japan;(27)Shimane University Faculty of Medicine, Department of Internal Medicine II, Izumo, Japan;(28)Nagoya City University West Medical Center, Gastroenterology, Nagoya, Japan;(29)Asahikawa Medical University, Department of Medicine, Asahikawa, Japan;(30)Okayama University Graduate School of Medicine- Dentistry and Pharmaceutical Sciences, Gastroenterology and Hepatology, Okayama, Japan;(31)Graduate School of Medicine- Kyoto University, Department of Gastroenterology and Hepatology, Kyoto, Japan;(32)The Jikei University School of Medicine, Division of Gastroenterology and Hepatology- Department of Internal Medicine, Tokyo, Japan;(33)The University of Tokyo, The Institute of Medical Science, Tokyo, Japan;J-COMBAT trial group